"it appears from the HL doc that a Ph3 trial on the effect of ABL on CKD might be on the cards.."
Was this determined by the chart that summarizes the development status of their pipeline drugs, found on page 9 of the IPO Summary? (Type 2 diabetes with coronary heart disease)
Koo